Pharming Group (OTCMKTS:PHGUF – Get Free Report) announced its quarterly earnings results on Thursday. The biotechnology company reported $0.01 earnings per share for the quarter, reports. The business had revenue of $106.50 million for the quarter, compared to analysts’ expectations of $89.72 million. Pharming Group had a net margin of 0.30% and a return on equity of 0.46%.
Pharming Group Price Performance
Shares of Pharming Group stock remained flat at $1.51 on Friday. Pharming Group has a 52 week low of $0.79 and a 52 week high of $2.17. The stock has a 50-day moving average price of $1.77 and a 200 day moving average price of $1.61. The company has a quick ratio of 2.39, a current ratio of 3.16 and a debt-to-equity ratio of 0.46.
Pharming Group Company Profile
Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.
Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.
Recommended Stories
- Five stocks we like better than Pharming Group
- The gold chart Wall Street is terrified of…
- Elon Musk already made me a “wealthy man”
- Silver paying 20% dividend. Plus 68% share gains
- Unlocked: Elon Musk’s Next Big IPO
- 1,500 Banks Just Handed the Fed Your Bank Account
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
